Science Topics for Companies and Researchers 2022/04/21
The results of the Phase 1 trial have been published in a paper for the gut microbiota drug VE303, which was developed with Professor Kim Im-gi ( Center for Drug Discovery ; then a senior scientist at Vedanta Biosciences, Inc.) as an inventor. VE303 is a cocktail of eight intestinal bacteria strains, and he was responsible for determining its composition and confirming its efficacy in animal studies. The Phase 2 trial has now been completed, and development is underway toward commercialization.
Cell Host & Microbe